The clinical trial tested the efficacy of therapy, with enrollment based on tissue-based PCR and next-generation sequencing (NGS)–based local assay results with confirmation by clinical trial assay [CTA; the investigational Qiagen Therascreen BRAF V600E RGQ PCR Kit (Qiagen)] or enrollment through CTA to select patients with colorectal cancer whose tumors harbor the BRAFV600E alteration. Here, BRAF is linked to colorectal cancer.